



December 10, 2024

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street, Fort  
Mumbai - 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex, Bandra (E)  
Mumbai - 400 051

Scrip Code: **530019**

Symbol: **JUBLPHARMA**

**Sub: Credit Rating**

Dear Sirs,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that India Ratings and Research Private Limited has affirmed Long-term issuer rating of 'IND AA+' Rating for Jubilant Pharmova Limited with revision in outlook to 'Stable' from 'Negative' earlier. Revision in outlook is on account of healthy improvement in the Company's financial performance and credit metrics in H1'FY25, which was led by improvement in CDMO Sterile Injectibles and Generics businesses. The instrument-wise ratings are given below:

Sr. No.	Rating For	Amount (Rs. Crore)	Credit Rating
1.	Fund-based Working Capital limits	150.00	IND AA+/Stable/IND A1+
2.	Non-fund-based Working Capital limits	150.00	IND A1+
3.	Term loans	200.00	IND AA+/Stable

The Company has received the rating letter from India Ratings and Research Private Limited on December 9, 2024 at 07:12 pm.

This is for your kind information and record.

Thanking you,

Yours faithfully,

For Jubilant Pharmova Limited

Naresh Kapoor  
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



**Jubilant Pharmova Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
www.jubilantpharmova.com

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223  
UP, India  
CIN : L24116UP1978PLC004624